Division of BridgeBio Pharma Inc.
Latest From QED Therapeutics
The company emerged in 2017 with $135m to spin out rare genetic disease-focused subsidiaries. Now with 18 start-ups and two near-term filings for drug approvals, BridgeBio will fund existing programs as they progress and continue to buy new assets.
Basilea reported positive interim results from its registrational Phase II study with oncology drug candidate derazantinib in intrahepatic cholangiocarcinoma, or bile duct cancer.
Moderna raised $500m to fund its growing pipeline, choosing once again to stay private rather than pursue an IPO. Also, AvroBio closed a $60m Series B round to advance its gene therapies for lysosomal storage disorders, Seattle Genetics led recent public company financings, and Vical is restructuring.
- Therapeutic Areas
- North America
- Company Type
- Parent & Subsidiaries
- BridgeBio Pharma Inc.
- Senior Management
- Daniel Hoth, MD, CMO
- Contact Info
Phone: (650) 391-9740
421 Kipling St.
Palo Alto, CA 94301
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.